{"nct_id":"NCT03821935","title":"Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","status_verified_date":"2025-05","start_date":"2019-02-21","start_date_type":"ACTUAL","primary_completion_date":"2027-06","primary_completion_date_type":"ESTIMATED","completion_date":"2027-06","completion_date_type":"ESTIMATED","phases":["PHASE1"],"tickers":["ABBV"]}